Free Trial

Cryo-Cell International Q2 2023 Earnings Report

Cryo-Cell International logo
$7.83 -0.07 (-0.89%)
(As of 12/20/2024 04:32 PM ET)

Cryo-Cell International EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.07
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Cryo-Cell International Revenue Results

Actual Revenue
$7.77 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cryo-Cell International Announcement Details

Quarter
Q2 2023
Time
Q2 2023 Earnings Release

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Cryo-Cell International Earnings Headlines

CRYO-CELL International, Inc. trading resumes
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
CRYO-CELL International, Inc. trading halted, volatility trading pause
See More Cryo-Cell International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cryo-Cell International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cryo-Cell International and other key companies, straight to your email.

About Cryo-Cell International

Cryo-Cell International (NYSEAMERICAN:CCEL) engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

View Cryo-Cell International Profile

More Earnings Resources from MarketBeat

Upcoming Earnings